CE: 1776 CF: cag11418
SCIENTIFIC ARTICLE
Biological efficacy of Sphere Max 535 SC fungicide for the control of anthracnose in papaya
Eficacia biológica del fungicida Sphere Max 535 SC para el control de la antracnosis en papaya
Amaurys Dávila Martínez1*, Lidcay Herrera Isla2, Maryluz Folgueras Montiel1, Dahert García Hernández1
1Laboratorio Fitopatología, Dirección Manejo de Plagas, Instituto de Investigaciones de Viandas Tropicales (INIVIT). Apartado 6, Santo Domingo, Villa Clara, Cuba, CP 53 000, This email address is being protected from spambots. You need JavaScript enabled to view it.; This email address is being protected from spambots. You need JavaScript enabled to view it.
2Universidad Central "Marta Abreu" de Las Villas (UCLV), Facultad de Ciencias Agropecuarias. Carretera a Camajuaní km 5 ½, Santa Clara, Villa Clara, Cuba, CP 54830, This email address is being protected from spambots. You need JavaScript enabled to view it.
*E-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.
ABSTRACT
Papaya crop (Carica papaya L.) faces pathologies mainly of fungal etiology. Colletotrichum gloeosporioides (Penz.) Sacc., causal agent of anthracnose, represents one of the most severe diseases that reduce the productivity of plantations. For this reason, the present study was carried out on one hectare of papaya cultivar 'Maradol Roja' at the Research Institute of Tropical Root and Tuber Crops (INIVIT), with the objective of evaluating the technical effectiveness of the fungicide Sphere Max 535 SC (trifloxystrobin + ciproconazole) for the control of anthracnose at doses of 0.2 and 0.3 L ha-1 and Biobeno (Benomilo), the latter as a commercial reference. A completely randomized design was used; five applications were made with a frequency of 20 days. The severity of the disease was evaluated, as well as the technical effectiveness of the formulations used. The severity increased gradually, reaching its maximum values at 100 days. In the plots treated with Benomilo, the severity of the disease was higher, reaching an average of 22.3 %. The variants corresponding to Sphere Max 535 SC were more effective than Benomilo, with values of 57,8 and 61,5 % of effectiveness, respectively.
